Global Ovarian Cancer Drugs Market 2017 Size, Share, Forecasts to 2022

Published On: Aug 2017

Format: PDF

Publisher: QY Research

Pages: 125

Report ID: 107489

This report studies Ovarian Cancer Drugs in Global market, especially in North America, Europe, China, Japan, Latin America and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering
Roche
Boehringer Ingelheim
Amgen
AstraZeneca
GlaxoSmithKline
ABRAXANE
Doxil
Exelixis
DelMar Pharmaceuticals Inc
Bristol-Myers Squibb
Celgene
Alkeran
Lynparza
Novartis Pharmaceuticals Corp
Clovis Oncology
Alza

Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Ovarian Cancer Drugs in these regions, from 2011 to 2021 (forecast), like
North America
China
Europe
Japan
Latin America
India
Row

Split by Product Types, with production, revenue, price, market share and growth rate of each type, can be divided into
Oral Therapy
Injectable Therapy
Others

Split by applications, this report focuses on consumption, market share and growth rate of Ovarian Cancer Drugs in each application, can be divided into
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Others


Table of Contents

1 Ovarian Cancer Drugs Market Overview
1.1 Product Overview and Scope of Ovarian Cancer Drugs
1.2 Ovarian Cancer Drugs Segment by Types
1.2.1 Global Production Market Share of Ovarian Cancer Drugs by Types in 2016
1.2.2 Oral Therapy
1.2.3 Injectable Therapy
1.2.4 Others
1.3 Ovarian Cancer Drugs Segment by Applications
1.3.1 Ovarian Cancer Drugs Consumption Market Share by Applications in 2016
1.3.2 Chemotherapy
1.3.3 Targeted Therapy
1.3.4 Immunotherapy (Biologic Therapy)
1.3.5 Others
1.4 Ovarian Cancer Drugs Market by Regions
1.4.1North America Status and Prospect (2012-2022)
1.4.2 China Status and Prospect (2012-2022)
1.4.3 Europe Status and Prospect (2012-2022)
1.4.4 Japan Status and Prospect (2012-2022)
1.4.5 Latin America Status and Prospect (2012-2022)
1.4.6 India Status and Prospect (2012-2022)
1.4.7 Row Status and Prospect (2012-2022)
1.5 Global Market Size (Value) of Ovarian Cancer Drugs (2012-2022)
2 Global Ovarian Cancer Drugs Market Competition by Manufacturers
2.1 Global Ovarian Cancer Drugs Capacity, Production and Share by Manufacturers (2015 and 2016)
2.2 Global Ovarian Cancer Drugs Revenue and Share by Manufacturers (2015 and 2016)
2.3 Global Ovarian Cancer Drugs Average Price by Manufacturers (2015 and 2016)
2.4 Manufacturers Ovarian Cancer Drugs Manufacturing Base Distribution, Sales Area, Product Types
2.5 Ovarian Cancer Drugs Market Competitive Situation and Trends
2.5.1 Ovarian Cancer Drugs Market Concentration Rate
2.5.2 Ovarian Cancer Drugs Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion
3 Global Ovarian Cancer Drugs Capacity, Production, Revenue (Value) by Regions (2012-2017)
3.1 Global Ovarian Cancer Drugs Capacity and Market Share by Regions (2012-2017)
3.2 Global Ovarian Cancer Drugs Production and Market Share by Regions (2012-2017)
3.3 Global Ovarian Cancer Drugs Revenue (Value) and Market Share by Regions (2012-2017)
3.4 Global Ovarian Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.5North America Ovarian Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.6 Europe Ovarian Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.7 China Ovarian Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.8 Japan Ovarian Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.9 Latin America Ovarian Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.10 India Ovarian Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
3.11 Row Ovarian Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
4 Global Ovarian Cancer Drugs Supply (Production), Consumption, Export, Import by Regions (2012-2017)
4.1 Global Ovarian Cancer Drugs Consumption by Regions (2012-2017)
4.2North America Ovarian Cancer Drugs Production, Consumption, Export, Import by Regions (2012-2017)
4.3 Europe Ovarian Cancer Drugs Production, Consumption, Export, Import by Regions (2012-2017)
4.4 China Ovarian Cancer Drugs Production, Consumption, Export, Import by Regions (2012-2017)
4.5 Japan Ovarian Cancer Drugs Production, Consumption, Export, Import by Regions (2012-2017)
4.6 Latin America Ovarian Cancer Drugs Production, Consumption, Export, Import by Regions (2012-2017)
4.7 India Ovarian Cancer Drugs Production, Consumption, Export, Import by Regions (2012-2017)
4.8 Row Ovarian Cancer Drugs Production, Consumption, Export, Import by Regions (2012-2017)
5 Global Ovarian Cancer Drugs Production, Revenue (Value), Price Trend by Types
5.1 Global Ovarian Cancer Drugs Production and Market Share by Types (2012-2017)
5.2 Global Ovarian Cancer Drugs Revenue and Market Share by Types (2012-2017)
5.3 Global Ovarian Cancer Drugs Price by Type (2012-2017)
5.4 Global Ovarian Cancer Drugs Production Growth by Type (2012-2017)
6 Global Ovarian Cancer Drugs Market Analysis by Applications
6.1 Global Ovarian Cancer Drugs Consumption and Market Share by Applications (2012-2017)
6.2 Global Ovarian Cancer Drugs Consumption Growth Rate by Applications (2012-2017)
6.3 Market Drivers and Opportunities
6.3.1 Potential Applications
6.3.2 Emerging Markets/Countries
7 Global Ovarian Cancer Drugs Manufacturers Profiles/Analysis
7.1 Roche
7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2 Ovarian Cancer Drugs Product Types, Application and Specification
7.1.2.1 Oral Therapy
7.1.2.2 Injectable Therapy
7.1.3 Roche Ovarian Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
7.2 Boehringer Ingelheim
7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.2.2 Ovarian Cancer Drugs Product Types, Application and Specification
7.2.2.1 Oral Therapy
7.2.2.2 Injectable Therapy
7.2.3 Boehringer Ingelheim Ovarian Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
7.3 Celgene
7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.3.2 Ovarian Cancer Drugs Product Types, Application and Specification
7.3.2.1 Oral Therapy
7.3.2.2 Injectable Therapy
7.3.3 Celgene Ovarian Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
7.4 Amgen
7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.4.2 Ovarian Cancer Drugs Product Types, Application and Specification
7.4.2.1 Oral Therapy
7.4.2.2 Injectable Therapy
7.4.3 Amgen Ovarian Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
7.5 AstraZeneca
7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.5.2 Ovarian Cancer Drugs Product Types, Application and Specification
7.5.2.1 Oral Therapy
7.5.2.2 Injectable Therapy
7.5.3 AstraZeneca Ovarian Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
7.6 GlaxoSmithKline
7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.6.2 Ovarian Cancer Drugs Product Types, Application and Specification
7.6.2.1 Oral Therapy
7.6.2.2 Injectable Therapy
7.6.3 GlaxoSmithKline Ovarian Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
7.7 ABRAXANE
7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.7.2 Ovarian Cancer Drugs Product Types, Application and Specification
7.7.2.1 Oral Therapy
7.7.2.2 Injectable Therapy
7.7.3 ABRAXANE Ovarian Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
7.8 Doxil
7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.8.2 Ovarian Cancer Drugs Product Types, Application and Specification
7.8.2.1 Oral Therapy
7.8.2.2 Injectable Therapy
7.8.3 Doxil Ovarian Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
7.9 Exelixis
7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.9.2 Ovarian Cancer Drugs Product Types, Application and Specification
7.9.2.1 Oral Therapy
7.9.2.2 Injectable Therapy
7.9.3 Exelixis Ovarian Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
7.10 DelMar Pharmaceuticals Inc
7.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.10.2 Ovarian Cancer Drugs Product Types, Application and Specification
7.10.2.1 Oral Therapy
7.10.2.2 Injectable Therapy
7.10.3 DelMar Pharmaceuticals Inc Ovarian Cancer Drugs Capacity, Production, Revenue, Price and Gross Margin (2015 and 2016)
7.11 Bristol-Myers Squibb
7.12 Celgene
7.13 Alkeran
7.14 Lynparza
7.15 Novartis Pharmaceuticals Corp
7.16 Clovis Oncology
7.17 Alza
8 Ovarian Cancer Drugs Manufacturing Cost Analysis
8.1 Ovarian Cancer Drugs Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Price Trend of Key Raw Materials
8.1.3 Key Suppliers of Raw Materials
8.1.4 Market Concentration Rate of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.2.1 Raw Materials
8.2.2 Labor Cost
8.2.3 Manufacturing Expenses
8.3 Manufacturing Process Analysis of Ovarian Cancer Drugs
9 Targeted Therapy Chain, Sourcing Strategy and Downstream Buyers
9.1 Ovarian Cancer Drugs Targeted Therapy Chain Analysis
9.2 Upstream Raw Materials Sourcing
9.3 Raw Materials Sources of Ovarian Cancer Drugs Major Manufacturers in 2016
9.4 Downstream Buyers
10 Marketing Strategy Analysis, Distributors/Traders
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
11 Market Effect Factors Analysis
11.1 Technology Progress/Risk
11.1.1 Substitutes Threat
11.1.2 Technology Progress in Related Industry
11.2 Consumer Needs/Customer Preference Change
11.3 Economic/Political Environmental Change
12 Global Ovarian Cancer Drugs Market Forecast (2017-2022)
12.1 Global Ovarian Cancer Drugs Capacity, Production, Revenue Forecast (2017-2022)
12.2 Global Ovarian Cancer Drugs Production, Consumption Forecast by Regions (2017-2022)
12.3 Global Ovarian Cancer Drugs Production Forecast by Type (2017-2022)
12.4 Global Ovarian Cancer Drugs Consumption Forecast by Application (2017-2022)
12.5 Ovarian Cancer Drugs Price Forecast (2017-2022)
13 Research Findings and Conclusion
14 Appendix
Author List
Disclosure Section
Research Methodology
Data Source
Disclaimer